s-1743 has been researched along with Chemical-and-Drug-Induced-Liver-Injury* in 2 studies
2 other study(ies) available for s-1743 and Chemical-and-Drug-Induced-Liver-Injury
| Article | Year |
|---|---|
A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance.
We describe a case report of a patient who developed transient type 2 diabetes after a drug-induced (esomeprazole) sub-acute hepatitis. This case evidences the pathophysiological relevance, also in humans, of liver inflammation in the pathogenesis of type 2 diabetes. Topics: Anti-Ulcer Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Esomeprazole; Humans; Inflammation; Insulin Resistance; Male; Middle Aged | 2014 |
[Cytolytic hepatitis and esomeprazole during chemotherapy].
Esomeprazole, the pure S isomer form of omeprazole, is indicated for the treatment of peptic esophagitis. We report here a major episode of cytolytic hepatitis following a single administration.. A 41-year-old woman with infiltrating ductal carcinoma of the breast was undergoing chemotherapy with paclitaxel and trastuzumab. On the fourth day of the second course, she took 1 tablet of esomeprazole 20 mg for epigastric pain. Liver pain and asthenia followed, and liver function tests showed substantial cytolysis. These tests returned to normal levels despite continuation of the chemotherapy.. This cytolytic hepatitis is very probably imputable to esomeprazole, but a synergistic hepatic toxicity of the chemotherapy with esomeprazole cannot be ruled out. Topics: Adult; Anti-Ulcer Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemical and Drug Induced Liver Injury; Esomeprazole; Esophagitis; Female; Humans; Paclitaxel; Trastuzumab | 2005 |